## Abstract ## BACKGROUND Aggressive treatment of early stage prostate carcinoma (PC) is limited primarily to two modalities: radical prostatectomy (RP) and external beam radiation therapy (RT). The authors conducted a populationβbased study of Detroit area men with localized PC to determine the o
Cryosurgery as a treatment for prostate carcinoma : Results and complications
β Scribed by Wilson S. Wong; Douglas O. Chinn; Mahlon Chinn; James Chinn; Wynnyee L. Tom; Wynnmian L. Tom
- Publisher
- John Wiley and Sons
- Year
- 1997
- Tongue
- English
- Weight
- 739 KB
- Volume
- 79
- Category
- Article
- ISSN
- 0008-543X
No coin nor oath required. For personal study only.
β¦ Synopsis
Background:
There has been a resurgence of interest in cryosurgical ablation of the prostate for the treatment of carcinoma. this is due to recent advances in cryosurgical technology, which have resulted in relatively lower morbidity. the objective of this study was to evaluate the effectiveness of ultrasound-guided cryosurgical ablation of prostate carcinoma.
Methods:
Eighty-three patients who had biopsy-proven prostate carcinoma underwent cryosurgical ablation of their entire prostate gland. the initial group of 12 patients had their procedures performed under ultrasound guidance only. the other 71 patients had cryosurgery performed with temperature monitoring in combination with ultrasound guidance. twelve patients who had positive biopsies underwent a second cryosurgical procedure. all patients had prostate specific antigen (psa) levels measured at 3, 6, 12, 18, 24, and 30 months after cryosurgery. ultrasound-guided sextant biopsies were performed at 3-6, 12-18, and 24 months.
Results:
The median psa dropped by 95%, from a preoperative value of 4.3 ng/ml to 0.2 ng/ml 30 months after cryosurgery. the authors experienced a high failure rate (positive biopsies) of 83% for the initial group of 12 patients who did not have temperature monitoring during the cryosurgical procedure. this was in contrast to a success rate of 90% (negative biopsies) for the next 71 patients, who did have temperature monitoring (p < 0.05, chi-square test). twelve patients underwent a second cryosurgery, and the success rate for this group was 91% (11 of 12 patients). the combined success rate for both the first cryosurgery and the second was 94% (62 of 77 patients). complications included urethral sloughing, urinary incontinence, impotence, bladder neck contracture, and bladder contracture. the majority of patients recovered rapidly from their cryosurgical procedures and were able to resume normal activities 3-4 weeks afterward.
Conclusions:
These preliminary results demonstrate that cryosurgical ablation of the prostate is a viable treatment option for prostate carcinoma. in the authors' experience, ultrasound alone may not be adequate for monitoring the entire cryosurgical procedure. the authors found that temperature monitoring shortened their learning curve, enabled them to freeze prostate tissue more aggressively, and may have contributed to their overall success.
π SIMILAR VOLUMES
## Abstract ## BACKGROUND Men with earlyβstage prostate carcinoma can choose aggressive treatment or conservative management. The authors used data from a populationβbased cohort of men with clinically localized prostate carcinoma to describe satisfaction with treatment decisions 24 months after d
Background. Oral tongue cancer may be treated primarily with radiotherapy or with surgery alone or combined with adjuvant radiotherapy; the choice between these two approaches is controversial. Methods. To evaluate the results of a shift in treatment policy in 1985 in favor of primary surgical trea
## Abstract ## BACKGROUND The objective of this survey was to identify factors associated with good sexual outcomes in a large group of survivors of localized prostate carcinoma. ## METHODS A postal survey was sent to 2636 men in the Cleveland Clinic Foundation's Prostate Cancer Registry who eit
Northeast Urological Specialty, Albany Memo-Drs. Miller and Cohen both receive honoraria and own stock in Cynomedical Sciences, Inc.